Sandoz, Polpharma score European approval for first Tysabri biosimilar for multiple sclerosis
Following quickly on the heels of US biosimilar approvals, Amsterdam-based Polpharma Biologics scored a European Commission authorization for its Tysabri (natalizumab) biosimilar for multiple sclerosis, the company announced Tuesday.
The biosimilar, marketed as Tyruko, was developed by Polpharma but will be commercialized by its partner Sandoz, thanks to a 2019 agreement. The FDA approved Tyruko in August, making it the first-ever natalizumab biosimilar in the US. The EC authorization also marks the first biosimilar for the drug to come to market in Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.